Summit Therapeutics Inc share price logo

Summit Therapeutics Inc Share Price

NASDAQ: SMMT

Mid Cap

$18.94

as on

Summit Therapeutics Inc Stock Performance

as on September 16, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $18.05
    $19.13
    downward going graph

    4.70%

    Downside

    1.00%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $15.55
    $36.91
    downward going graph

    17.90%

    Downside

    94.88%

    Upside

    downward going graph

Summit Therapeutics Inc share price movements today

Previous Close
$18.94
Open
$18.98
Volume
4.2M
Day's Low - High
$18.05 - $19.13
52 Week Low - High
$15.55 - $36.91

Summit Therapeutics Inc Historical Returns

1 Month Return
-29.04 %
3 Month Return
-4.25 %
1 Year Return
-40.68 %
3 Year Return
+ 1262.59 %
5 Year Return
0 %

Summit Therapeutics Inc Stock Fundamentals & Key Indicators

Check Summit Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$14.1B

EPS (TTM)

-0.7023

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-15.59

Industry PE ratio

10.127857142857144

P/B Ratio

0

PEG Ratio

0

EBITDA

-759.2M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

155400.00%

Summit Therapeutics Inc Stock Valuation

Track how Summit Therapeutics Inc P/E has moved over time to understand its valuation trends.

Summit Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (0.00x)

September 15, 2025

Today (-15.59x)

September 15, 2025

Industry (10.13x)

September 15, 2025

Highest (-0.61x)

April 30, 2023

LowHigh

Today’s Price to Earnings Ratio: -15.59x

Summit Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Summit Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$14.1BNA-15.590.00%
BUY$61.1B256.98%-505.15-12.96%
NA$38.7BNANA-3.89%
BUY$101.1B47.85%28.0731.86%
BUY$59.4B-3.43%14.1131.37%

Stock Returns calculator for Summit Therapeutics Inc Stock including INR - Dollar returns

The Summit Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Summit Therapeutics Inc investment value today

Current value as on today

₹64,303

Returns

₹35,697

(-35.7%)

Returns from Summit Therapeutics Inc Stock

₹40,683 (-40.68%)

Dollar Returns*

₹4,985 (+4.99%)

Analyst Recommendation on Summit Therapeutics Inc Stock

Based on 7 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Summit Therapeutics Inc. Average target price of $34.52

Summit Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Summit Therapeutics Inc.

What analysts predicted

45.13%UPSIDE

Target Price

$34.52

Current Price

$18.94

Analyzed by

7 Analysts

Target

$34.52

Summit Therapeutics Inc target price $34.52, a slight upside of 45.13% compared to current price of $18.94. According to 7 analysts rating.

Summit Therapeutics Inc Stock's Interest Amongst Investors

Investment in Summit Therapeutics Inc Shares on INDmoney has grown by 159.63% over the past 30 days, indicating increased transactional activity.

Time period: to

Change:159.63% versus previous 30 day period

Search interest for Summit Therapeutics Inc Stock has increased by 16% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:16% versus previous 30 day period

Summit Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Oct 2023
Dec 2023
Jan 2024
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
-
0
0
-
-
-
-
-
-
Gross Profit
-
-1
-
0
0
0
-14
0
0
Operating Income
-
-28
-
-42
-59
-58
-65
-66
-568
EBITDA
-
-33
-
-40
-57
-53
-61
-62
-565
Interest Expense
-
2
-
3
3
2
0
-
-
Depreciation
-
0
-
0
0
0
0
0
0
Income Before Tax
-
-36
-
-43
-60
-56
-61
-62
-565
Income Tax Expense
-
2
-
3
0
0
0
-
-
Net Income
-21
-36
-36
-55
-76
-74
-61
-62
-565
Net Profit Margin
0.00%
12205.96%
15560.43%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Summit Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Jan 2020
Dec 2020
Jan 2021
Dec 2021
Jan 2022
Dec 2022
Jan 2023
Dec 2023
Jan 2024
Dec 2024
Total Revenue
56
1
1
2
2
0
0
-
-
-
Gross Profit
-
1
-
2
-
-2
-
-2
-
-15
Operating Income
-
-53
-
-86
-
-59
-
-89
-
0
EBITDA
-
-50
-
-83
-
-73
-
1
-
-212
Interest Expense
-
0
-
0
-
4
-
16
-
8
Depreciation
-
2
-
2
-
2
-
2
-
0
Income Before Tax
-
-52
-
-88
-
-78
-
-615
-
-221
Income Tax Expense
-
0
-
-2
-
-4
-
0
-
0
Net Income
6
-70
-71
-114
-116
-95
-90
-778
-614
-221
Net Profit Margin
11.61%
-6127.56%
-6127.56%
-4762.13%
-4762.13%
-11185.94%
-10561.06%
0.00%
0.00%
0.00%

Summit Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-14
-21
-36
-43
-60
-56
-61
-62
-565
Operating Cash Flow
-29
-14
-19
-30
-32
-30
-48
-61
-66
Investing Cash Flow
0
-3
60
19
-199
-108
83
160
150
Financing Cash Flow
0
0
6
0
199
204
-23
7
2
Change in Cash
-28
-18
47
-9
-32
65
11
106
86

Summit Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-32
-15
6
-23
-52
-88
-78
-614
-221
Operating Cash Flow
15
-20
-35
-15
-48
-72
-41
-76
-142
Investing Cash Flow
0
-7
0
0
0
0
0
-587
-205
Financing Cash Flow
0
19
43
37
50
77
620
86
381
Change in Cash
14
-11
8
27
2
5
576
-577
33

Global Institutional Holdings in Summit Therapeutics Inc

Funds
Holdings
Baker Bros Advisors LP
3.29%
Vanguard Group Inc
1.57%
FMR Inc
1.26%
BlackRock Inc
1.13%
T. Rowe Price Associates, Inc.
0.88%

Insights on Summit Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, SMMT stock has moved up by 1368.2%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, SMMT has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 72.3% return, outperforming this stock by 108.1%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 235.0K → -235.0K (in $), with an average decrease of 100.0% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 4 quarters, -56.25M → -565.70M (in $), with an average decrease of 270.3% per quarter

About Summit Therapeutics Inc

summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.
OrganisationSummit Therapeutics Inc
Headquarters601 Brickell Key Drive, Miami, FL, United States, 33131
IndustryHealth Technology
CEOMr. Robert W. Duggan
E-voting on sharesClick here to vote

Key Management of Summit Therapeutics Inc

Name

Title

Dr. Mahkam Zanganeh D.D.S., M.B.A.

Co-CEO, President & Director

Mr. Manmeet Singh Soni CPA

COO, CFO & Director

Mr. Dave Gancarz

Chief Business & Strategy Officer

Ms. Shelley D. Spray

Chief Education & Brand Officer

Dr. Urte Gayko Ph.D.

Chief Regulatory, Quality & Pharmacovigilance Officer

Dr. Allen S. Yang M.D., Ph.D.

Chief Medical Officer

Mr. Robert W. Duggan

Co-CEO & Executive Chairman

Prof. Dame Kay Davies DBE, FRS CBE

Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor

Dr. Fong Clow

Chief Biometrics Officer

Dr. Laura Q. M. Chow M.D.

Senior Vice President of Clinical Development

FAQs

What is Summit Therapeutics Inc share price today?

Summit Therapeutics Inc share price today is $18.94 as on at the close of the market. Summit Therapeutics Inc share today touched a day high of $19.13 and a low of $18.05.

What is the 52 week high and 52 week low for Summit Therapeutics Inc share?

Summit Therapeutics Inc share touched a 52 week high of $36.91 on and a 52 week low of $15.55 on . Summit Therapeutics Inc stock price today i.e. is closed at $18.94,which is 48.69% down from its 52 week high and 21.80% up from its 52 week low.

What is Summit Therapeutics Inc's market capitalisation today?

Summit Therapeutics Inc market capitalisation is $0.01T as on .

How to invest in Summit Therapeutics Inc Stock (SMMT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Summit Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Summit Therapeutics Inc Shares that will get you 0.0792 shares as per Summit Therapeutics Inc share price of $18.94 per share as on September 16, 2025 at 1:29 am IST.

What is the minimum amount required to buy Summit Therapeutics Inc Stock (SMMT) from India?

Indian investors can start investing in Summit Therapeutics Inc (SMMT) shares with as little as ₹88.141 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Summit Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Summit Therapeutics Inc share’s latest price of $18.94 as on September 16, 2025 at 1:29 am IST, you will get 0.5280 shares of Summit Therapeutics Inc. Learn more about fractional shares .